Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MediWound Ltd. - Ordinary Shares (NQ: MDWD )

18.76 +0.14 (+0.75%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
MediWound's EscharEx Mid-Stage Trial Meets Primary Goal In Venous Leg Ulcers
MediWound Ltd (NASDAQ: MDWD) has posted topline results from its U.S. Phase 2 study of EscharEx for the debridement (removal of dead or infected skin tissue for... 
Via Benzinga
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis... 
Via Benzinga
Earnings Scheduled For November 16, 2021
Companies Reporting Before The Bell • Ozon Holdings (NASDAQ:OZON) is expected to report quarterly loss at $0.90 per share on revenue of $602.00 million. • Sea (... 
Via Benzinga
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter. • Fulcrum Therapeutics (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
MediWound Earnings Preview
MediWound (NASDAQ:MDWD) releases its next round of earnings this Wednesday, May 05. Here is Benzinga's essential guide to MediWound's Q1 earnings report. What Are Earnings, Net... 
Via Benzinga
Earnings Preview For MediWound
MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Tuesday, 2021-11-16. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
MediWound's Earnings: A Preview
On Tuesday, August 10, MediWound (NASDAQ:MDWD) will release its latest earnings report. Benzinga's outlook for MediWound is included in the following report. Net Income, Earnings... 
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer
MediWound Ltd (NASDAQ: MDWD) has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC). In parallel, an investigator-initiated... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
28 Stocks Moving in Wednesday's Pre-Market Session
Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares rose 78.2% to $3.67 in pre-market trading after dropping more than 16% on Tuesday. Chembio’s filing recently showed... 
Via Benzinga
MediWound's NexoBrid Shows Significant Beneficial Impact On Pediatric Burn Patients
MediWound Ltd (NASDAQ: MDWD) has announced topline results from Phase 3 pediatric study with NexoBrid to treat severe thermal burns. The 145-subject study... 
Via Benzinga
20 Stocks Moving in Thursday's Pre-Market Session
Gainers Alterity Therapeutics Ltd (NASDAQ: ATHE) shares rose 64% to $2.14 in pre-market trading. Alterity Therapeutics recently said it received EU regulatory guidance for ATH434... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers BSQUARE Corporation (NASDAQ: BSQR) shares jumped 206.9% to close at $8.04 on Tuesday on abnormally-high volume possibly amid increased attention from retail investors.... 
Via Benzinga
Mid-Afternoon Market Update: US Stocks Mostly Flat; DiaMedica Therapeutics Shares Plunge
Toward the end of trading Tuesday, the Dow traded up 0.04% to 34,295.41 while the NASDAQ rose 0.13% to 14,518.98. The S&P traded flat at 4,290.65. The U.S. has the highest... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Shares Of MediWound And Vericel Fell On Tuesday
Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the... 
Via Benzinga
Mid-Day Market Update: Gold Drops Over 1%; Cerevel Therapeutics Shares Spike Higher
Midway through trading Tuesday, the Dow traded up 0.37% to 34,411.60 while the NASDAQ fell 0.03% to 14,495.75. The S&P also rose, gaining 0.16% to 4,297.63. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
35 Stocks Moving In Tuesday's Mid-Day Session
Gainers Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) shares jumped 111.5% to $26.58 after the company announced positive results from its Phase 1b clinical trial of CVL-231... 
Via Benzinga
Mid-Morning Market Update: Markets Mostly Higher; FactSet Research Reports Mixed Q3 Results
Following the market opening Tuesday, the Dow traded up 0.40% to 34,420.32 while the NASDAQ fell 0.10% to 14,486.23. The S&P also rose, gaining 0.14% to 4,296.59. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Strikes Off MediWound - Vericel's NexoBrid Biologics License Application; Stocks Drop
Vericel Corporation's (NASDAQ:VCEL) devel... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,... 
Via Benzinga
24 Stocks Moving in Monday's Pre-Market Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim... 
Via Benzinga
55 Biggest Movers From Friday
Gainers IKONICS Corporation (NASDAQ: IKNX) shares surged 64.3% to close at $18.56 on Friday after the company reported a merger deal with TeraWulf. Alpha Teknova, Inc. (NASDAQ:... 
Via Benzinga
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (NYSE: LLY) stood out among big... 
Via Benzinga
Exposures Product Safety
66 Biggest Movers From Yesterday
Gainers Orphazyme A/S (NASDAQ: ORPH) shares jumped 302.3% to close at $21.00 on Thursday. Shares of the biopharmaceutical firm touched an intraday high of $77.77, running up 1,... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.